$0.32
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

Xtant Medical Holdings, Inc. designs, and develops orthobiologics and spinal implant fixation systems to facilitate spinal fusion in complex spine, deformity, and degenerative procedures. The company is headquartered in Belgrade Montana, Montana and currently employs 151 full-time employees. The company went IPO on 2010-06-30. The firm's products serve the specialized needs of orthopedic and neurological surgeons, as well as trauma, foot and ankle, sports medicine, wound care surgeons including orthobiologics for the promotion of bone healing, amniotic tissue and collagen for both surgical repair and chronic wound care, implants and instrumentation for the treatment of spinal disease. Its orthobiologics products include OsteoSponge, OsteoSelect DBM Putty, OsteoSelect PLUS DBM Putty, 3Demin, OsteoFactor Pro, OsteoVive Plus, and nanOss. Its spinal implant product categories include cervical, thoracolumbar, sacroiliac joint, and interbody. The firm has exclusive United States distribution rights to Dilon's HEMOBLAST Bellows.
Country

US

CEO

Mr. Sean Browne

IPO date

2010

Employees

151

ISIN

US98420P3082

Key stats

Open

$0.33

Volume

143.97K

Market cap

$60.65M

Prev. close

$0.32

Impl / hst vl

-

Open interest

$0.00

$0.31

Day’s Range

$0.34

$0.27

52W Range

$0.78

Valuation

61
Valuation score
Undervalued
P/E
23.84
P/S
0.36
P/B
0.90
Current ratio
-
Debt / Equity
-
ROE
-
Gross margin
-
Income growth
204.73%
FCF growth
227.34

Analysts estimates

Consensus rating
Buy

The average rating from top 5 analysts indicates that stock is expected to perform in line with the market

Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$1.38
The top 4 analysts forecasts that 12-month price may increase by 330.31%, with a low of $1.21 and a high of $1.58
$1.21
Low
$1.38
Avg
$1.58
High
Current price

Earnings

Q2 ‘26 revenue
$23.03M
Q2 ‘26 net income
-$9.41M
Revenue
Net income
Previous EPS
-$0.02
Estimate EPS
-$0.02
Actual EPS
Estimate EPS
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply